# A versatile soluble siglec scaffold for sensitive and quantitative detection of glycan ligands

## TL;DR

Researchers developed a new method using Siglec-Fc proteins to detect and study glycan ligands on healthy and cancerous cells, revealing important patterns and implications for diseases like Alzheimer's.

## Contribution

A novel Siglec-Fc protein scaffold enables sensitive and quantitative detection of glycan ligands with improved selectivity and applicability.

## Key findings

- Siglec ligand patterns differ between healthy and cancerous cells and tissues.
- CD33 (Siglec-3) recognizes both α2-3 and α2-6 sialosides, linking it to Alzheimer’s disease susceptibility.
- A quantitative mass spectrometry assay was developed to determine Siglec ligand specificities.

## Abstract

Sialic acid-binding immunoglobulin-type lectins (Siglecs) are immunomodulatory receptors that are regulated by their glycan ligands. The connections between Siglecs and human disease motivate improved methods to detect Siglec ligands. Here, we describe a new versatile set of Siglec-Fc proteins for glycan ligand detection. Enhanced sensitivity and selectivity are enabled through multimerization and avoiding Fc receptors, respectively. Using these Siglec-Fc proteins, Siglec ligands are systematically profiled on healthy and cancerous cells and tissues, revealing many unique patterns. Additional features enable the production of small, homogenous Siglec fragments and development of a quantitative ligand-binding mass spectrometry assay. Using this assay, the ligand specificities of several Siglecs are clarified. For CD33 (Siglec-3), we demonstrate that it recognizes both α2-3 and α2-6 sialosides in solution and on cells, which has implications for its link to Alzheimer’s disease susceptibility. These soluble Siglecs reveal the abundance of their glycan ligands on host cells as self-associated molecular patterns.

Sialic acid-binding immunoglobulin-type lectins (Siglecs) are a family of immunomodulatory receptors expressed on cells of the hematopoietic lineage. Here the authors demonstrate an approach for the identification of the glycan ligands of Siglecs, which is also applicable to other families of glycan-binding proteins.